Search research articles
Contact Us
Filters
Showing results (411-420 of 511) with videos related to
Page
of 52
Sort By:
British Journal of Cancer
|
August 5, 2005
Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
G Ursin, L Bernstein, S J Lord, et al.
BMJ Open
|
September 24, 2020
The AEDUCATE Collaboration. Comprehensive antenatal education birth preparation programmes to reduce the rates of caesarean section in nulliparous women. Protocol for an individual participant data prospective meta-analysis
Kate M Levett, Sarah J Lord, Hannah G Dahlen, et al.
The Journal of Pathology
|
September 24, 2008
The genomic profile of HER2-amplified breast cancers: the influence of ER status
C Marchiò, R Natrajan, K K Shiu, et al.
BMC Medical Genomics
|
October 29, 2011
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines
Kevin C H Ha, Emilie Lalonde, Lili Li, et al.
Journal of Clinical Medicine
|
January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing
Irene Y Chong, Naureen Starling, Alistair Rust, et al.
Scientific Reports
|
January 19, 2019
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Malini Menon, Richard Elliott, Leandra Bowers, et al.
Nature Communications
|
December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Scientific Data
|
March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells
Stephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Cytotherapy
|
November 27, 2016
Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials
David H McKenna, Darin Sumstad, Diane M Kadidlo, et al.
Page
of 52
Search research articles
Search
Showing results (411-420 of 511) with videos related to
Sort By:
Page
of 52
British Journal of Cancer
|
August 5, 2005
Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
G Ursin, L Bernstein, S J Lord, et al.
BMJ Open
|
September 24, 2020
The AEDUCATE Collaboration. Comprehensive antenatal education birth preparation programmes to reduce the rates of caesarean section in nulliparous women. Protocol for an individual participant data prospective meta-analysis
Kate M Levett, Sarah J Lord, Hannah G Dahlen, et al.
The Journal of Pathology
|
September 24, 2008
The genomic profile of HER2-amplified breast cancers: the influence of ER status
C Marchiò, R Natrajan, K K Shiu, et al.
BMC Medical Genomics
|
October 29, 2011
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines
Kevin C H Ha, Emilie Lalonde, Lili Li, et al.
Journal of Clinical Medicine
|
January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing
Irene Y Chong, Naureen Starling, Alistair Rust, et al.
Scientific Reports
|
January 19, 2019
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Malini Menon, Richard Elliott, Leandra Bowers, et al.
Nature Communications
|
December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Scientific Data
|
March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells
Stephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Cytotherapy
|
November 27, 2016
Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials
David H McKenna, Darin Sumstad, Diane M Kadidlo, et al.
Page
of 52